Furthermore, we explored the clinical value of SPP1+CD68+ TAMs via IF staining in a cohort of 264 patients and it suggested that SPP1+ TAMs correlated with adverse clinical outcomes in ICC. The gene discussed is SPP1; the disease is intrahepatic cholangiocarcinoma.